In September, Valneva signed a partnership with the U.K. government to supply up to 190 million doses of VLA2001, which consists of inactivated SARS-CoV-2 virus particles with high S-protein density combined with two adjuvants: alum and CpG 1018. It is the only inactivated vaccine candidate in clinical trials in Europe, according to Valneva. If the vaccine is developed successfully, Valneva will supply the U.K. government with 60 million doses in the second half of this year.

Phase I/II of the study began in December 2020 and includes 150 healthy adults. It will evaluate three dose levels of the vaccine for safety, tolerability, and immunogenicity in a two-dose schedule three weeks apart, Valneva said.

U.S. increases order of Moderna mRNA COVID-19 vaccine to 300M doses
Moderna is in discussion with the U.S. government for the purchase of an additional 100 million doses of its messenger RNA (mRNA) COVID-19 vaccine,...

Regeneron publishes data supporting Ab cocktail as passive COVID-19 vaccine
Regeneron said that interim data from its ongoing phase III clinical trial supports the use of its Regen-CoV antibody (Ab) cocktail as a passive vaccine...

Medigen Vaccine, Dynavax begin phase II trial for subunit COVID-19 vaccine
Medigen Vaccine Biologics and Dynavax Technologies have dosed the first participant in a phase II clinical trial evaluating Medigen's COVID-19 vaccine...

Valneva begins clinical trials for inactivated, adjuvanted COVID-19 vaccine
Valneva has begun a phase I/II clinical trial to study its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Dynavax partners on Valneva's SARS-CoV-2 vaccine candidate
Dynavax will supply its CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001, as part of a commercial partnership.